Cargando…
Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223513/ https://www.ncbi.nlm.nih.gov/pubmed/37317279 http://dx.doi.org/10.3390/microorganisms11051305 |
_version_ | 1785049960100659200 |
---|---|
author | Zuccaro, Valentina Petazzoni, Greta Mileto, Irene Corbella, Marta Asperges, Erika Sacchi, Paolo Rattotti, Sara Varettoni, Marzia Defrancesco, Irene Cambieri, Patrizia Baldanti, Fausto Arcaini, Luca Bruno, Raffaele |
author_facet | Zuccaro, Valentina Petazzoni, Greta Mileto, Irene Corbella, Marta Asperges, Erika Sacchi, Paolo Rattotti, Sara Varettoni, Marzia Defrancesco, Irene Cambieri, Patrizia Baldanti, Fausto Arcaini, Luca Bruno, Raffaele |
author_sort | Zuccaro, Valentina |
collection | PubMed |
description | Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach to the treatment of chronic lymphocytic leukemia (CLL); however, not all patients achieve a satisfactory response, and immune-related adverse events (irAEs) can also impact the efficacy. The aim of the study was to compare GM biodiversity in patients with CLL, treated with BCRi for at least 12 months. Twelve patients were enrolled: 10 patients in the responder group (R) and 2 patients in the non-responder group (NR). We identified seven patients (58.3%) who experienced adverse reactions (AE). Although we did not observe a significant difference across the study population in terms of relative abundance and alpha and beta diversity, we found a differing distribution of bacterial taxa between the analyzed groups. We noted a higher level of the class Bacteroidia and the order Bacteroidales in the R group, and an inversion in the Firmicutes and Bacteroidetes ratio in the AE group. No prior studies have focused on linking GM and response to BCRi in these patients. Although the analyses are preliminary, they provide suggestions to guide future research. |
format | Online Article Text |
id | pubmed-10223513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102235132023-05-28 Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study Zuccaro, Valentina Petazzoni, Greta Mileto, Irene Corbella, Marta Asperges, Erika Sacchi, Paolo Rattotti, Sara Varettoni, Marzia Defrancesco, Irene Cambieri, Patrizia Baldanti, Fausto Arcaini, Luca Bruno, Raffaele Microorganisms Article Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach to the treatment of chronic lymphocytic leukemia (CLL); however, not all patients achieve a satisfactory response, and immune-related adverse events (irAEs) can also impact the efficacy. The aim of the study was to compare GM biodiversity in patients with CLL, treated with BCRi for at least 12 months. Twelve patients were enrolled: 10 patients in the responder group (R) and 2 patients in the non-responder group (NR). We identified seven patients (58.3%) who experienced adverse reactions (AE). Although we did not observe a significant difference across the study population in terms of relative abundance and alpha and beta diversity, we found a differing distribution of bacterial taxa between the analyzed groups. We noted a higher level of the class Bacteroidia and the order Bacteroidales in the R group, and an inversion in the Firmicutes and Bacteroidetes ratio in the AE group. No prior studies have focused on linking GM and response to BCRi in these patients. Although the analyses are preliminary, they provide suggestions to guide future research. MDPI 2023-05-17 /pmc/articles/PMC10223513/ /pubmed/37317279 http://dx.doi.org/10.3390/microorganisms11051305 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zuccaro, Valentina Petazzoni, Greta Mileto, Irene Corbella, Marta Asperges, Erika Sacchi, Paolo Rattotti, Sara Varettoni, Marzia Defrancesco, Irene Cambieri, Patrizia Baldanti, Fausto Arcaini, Luca Bruno, Raffaele Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title | Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title_full | Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title_fullStr | Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title_full_unstemmed | Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title_short | Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study |
title_sort | gut microbiota and b cell receptor (bcr) inhibitors for the treatment of chronic lymphocytic leukemia: is biodiversity correlated with clinical response or immune-related adverse event occurrence? a cross-sectional study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223513/ https://www.ncbi.nlm.nih.gov/pubmed/37317279 http://dx.doi.org/10.3390/microorganisms11051305 |
work_keys_str_mv | AT zuccarovalentina gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT petazzonigreta gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT miletoirene gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT corbellamarta gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT aspergeserika gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT sacchipaolo gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT rattottisara gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT varettonimarzia gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT defrancescoirene gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT cambieripatrizia gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT baldantifausto gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT arcainiluca gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy AT brunoraffaele gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy |